Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Northwestern University
Questions discussed in this category
In light of the recent rEECur trial interim analysis, would you offer high-dose ifosfamide to an AYA patient with relapsed Ewing's sarcoma who initially had a complete response to up-front therapy?
J Clin Oncol 40, 2022 (suppl 17; abstr LBA2). https://meetings.asco.org/abstracts-presentations/209024
2 Answers available
13106
Papers discussed in this category
Pediatr Blood Cancer, 2022 Oct 02
Irinotecan dose schedule for the treatment of Ewing sarcoma.
Clin Cancer Res, 2023 Jan 09
Longer versus shorter schedules of vincristine, irinotecan and temozolomide (VIT) for relapsed or refractory Ewing sarcoma: a randomized controlled phase 2 trial.
Related Topics
Pediatric Hematology/Oncology
NCI-CCC Tumor Board Question
AYA Tumor Board
Sarcoma
Ewing Sarcoma
ASCO 2022